WHAT IS CLAIMED IS:

1. A compound represented by Formula I:



I

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

Ar is phenyl or naphthyl;

m = 0 or 1;

n = 0 or 1;

A is selected from the group consisting of: $-CO_2H$, $-PO_3H_2$, $-PO_2H$, $-SO_3H$, $-PO(C_{1-3}alkyl)OH$ and 1*H*-tetrazol-5-yl;

R^1 and R^2 are each independently selected from the group consisting of: hydrogen, halo, hydroxy, $-CO_2H$ and $C_{1-4}alkyl$, optionally substituted from one up to the maximum number of substitutable positions with halo;

R^3 is selected from the group consisting of: hydrogen and $C_{1-4}alkyl$, optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo and hydroxy;

each R^4 is independently selected from the group consisting of: halo, $C_{1-4}alkyl$ and $C_{1-3}alkoxy$, said $C_{1-4}alkyl$ and $C_{1-3}alkoxy$ optionally substituted from one up to the maximum number of substitutable positions with halo,

C is selected from the group consisting of:

(1) C_{1-8}alkyl, C_{1-8}alkoxy, -(C=O)-C_{1-6}alkyl or –CHOH-C_{1-6}alkyl, said C_{1-8}alkyl, C_{1-8}alkoxy, -(C=O)-C_{1-6}alkyl and –CHOH-C_{1-6}alkyl optionally substituted with phenyl, and

(2) phenyl or HET, each optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, phenyl, C_{1-4}alkyl and C_{1-4}alkoxy, said C_{1-4}alkyl and C_{1-4}alkoxy groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy, and said phenyl optionally substituted with 1 to 5 groups independently selected from the group consisting of : halo and C_{1-4}alkyl, optionally substituted with 1-3 halo groups,

or **C** is not present;

when **C** is not present then **B** is selected from the group consisting of: phenyl, C_{5-16}alkyl, C_{5-16}alkenyl, C_{5-16}alkynyl, -CHOH-C_{4-15}alkyl, -CHOH-C_{4-15}alkenyl, -CHOH-C_{4-15}alkynyl, C_{4-15}alkoxy, -O-C_{4-15}alkenyl, -O-C_{4-15}alkynyl, C_{4-15}alkylthio, -S-C_{4-15}alkenyl, -S-C_{4-15}alkynyl, -CH_2-C_{3-14}alkoxy, -CH_2-O-C_{3-14}alkenyl, -CH_2-O-C_{3-14}alkynyl, -(C=O)-C_{4-15}alkyl, -(C=O)-C_{4-15}alkenyl, -(C=O)-C_{4-15}alkynyl, -(C=O)-O-C_{3-14}alkyl, -(C=O)-O-C_{3-14}alkenyl, -(C=O)-O-C_{3-14}alkynyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkenyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkynyl, -N(R^6)(R^7)-(C=O)-C_{3-14}alkyl, -N(R^6)(R^7)-(C=O)-C_{3-14}alkenyl and -N(R^6)(R^7)-(C=O)-C_{3-14}alkynyl,

when **C** is phenyl or HET then **B** is selected from the group consisting of: C_{1-6}alkyl, C_{1-5}alkoxy, -(C=O)-C_{1-5}alkyl, -(C=O)-O-C_{1-4}alkyl, -(C=O)-N(R^6)(R^7)-C_{1-4}alkyl,



, phenyl and HET, and

when **C** is C_{1-8}alkyl, C_{1-8}alkoxy, -(C=O)-C_{1-6}alkyl or –CHOH-C_{1-6}alkyl then **B** is phenyl; and

R^6 and R^7 are independently selected from the group consisting of: hydrogen, C_{1-9}alkyl and -$(CH_2)_p$-phenyl, wherein p is 1 to 5 and phenyl is optionally substituted with 1-3 substituents independently selected from the group consisting of: C_{1-3}alkyl and C_{1-3}alkoxy, each optionally substituted with 1-3 halo groups.

2. The compound according to Claim 1 wherein:

Ar is phenyl;

the group **–B-C** is attached to the phenyl ring at the 3- or 4-position;

C is phenyl or HET, each optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, phenyl, C_{1-4}alkyl and C_{1-4}alkoxy, said C_{1-4}alkyl and C_{1-4}alkoxy groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy, and said phenyl optionally substituted with 1 to 5 groups independently selected from the group consisting of : halo and C_{1-4}alkyl, optionally substituted with 1-3 halo groups,

or **C** is not present;

when **C** is not present then **B** is selected from the group consisting of: C_{7-12}alkyl, C_{7-12}alkenyl, C_{7-12}alkynyl, C_{6-11}alkoxy, -O-C_{6-11}alkenyl, -O-C_{6-11}alkynyl, -(C=O)-C_{6-11}alkyl, -(C=O)-C_{6-11}alkenyl, -(C=O)-C_{6-11}alkynyl, -(C=O)-O-C_{5-10}alkyl, -(C=O)-O-C_{5-19}alkenyl, and -(C=O)-O-C_{5-10}alkynyl and **C** is not present;

and

when **C** is phenyl or HET then **B** is selected from the group consisting of C_{1-5}alkyl, C_{1-4}alkoxy, -(C=O)-C_{1-4}alkyl, -(C=O)-O-C_{1-3}alkyl, phenyl and HET.

3. The compound according to Claim 1 wherein HET is selected from the group consisting of:



4. The compound according to Claim 1 wherein m is 0.

5. The compound according to Claim 1 wherein m is 1.

6. The compound according to Claim 1 wherein n is 0.

7. The compound according to Claim 1 wherein n is 1.

8. The compound according to Claim 1 wherein **B** is selected from the group consisting of: C_{7-12}alkyl, C_{7-12}alkenyl, C_{7-12}alkynyl, C_{6-11}alkoxy, -O-C_{6-11}alkenyl, -O-C_{6-11}alkynyl, -(C=O)-C_{6-11}alkyl, -(C=O)-C_{6-11}alkenyl, -(C=O)-

C_{6-11}alkynyl, -(C=O)-O-C_{5-10}alkyl, -(C=O)-O-C_{5-19}alkenyl, and -(C=O)-O-C_{5-10}alkynyl and **C** is not present.

9. The compound according to Claim 1 wherein:

B is methoxy and **C** is HET substituted with phenyl and C_1-4alkyl, said C_1-4alkyl optionally substituted from one up to the maximum number of substitutable positions with halo, and said phenyl, optionally substituted with 1 to 5 substituents independently selected from the group conisting of: halo and C_{1-4}alkyl, optionally substituted with 1-3 halo groups.

10. The compound according to Claim 8 wherein **C** is selected from the group consisting of:



11. The compound according to Claim 9 wherein **C** is thiophene or furan.

12. The compound according to Claim 1 wherein:

B is methoxy and **C** is HET.

13. The compound according to Claim 12 wherein **C** is selected from the group consisting of:



14. The compound according to Claim 13 wherein **C** is benzothiophene or benzofuran.

15. The compound according to Claim 1 wherein:

B is methoxy and **C** is phenyl substituted with two C_{1-4}alkyl groups, said C_{1-4}alkyl optionally substituted from one up to the maximum number of substitutable positions with halo.

16. The compound according to Claim 1 wherein:

B is HET and **C** is HET substituted with phenyl and C_{1-4}alkyl, said C_{1-4}alkyl optionally substituted from one up to the maximum number of substitutable positions with halo, and said phenyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of: halo, C_{1-4}alkyl, optionally substituted with 1-3 halo groups.

17. The compound according to Claim 16 wherein **B** is 1,2,4-oxadiazole.

18. The compound according to Claim 17 wherein **C** is selected from the group consisting of:



19. The compound according to Claim 18 wherein **C** is thiophene or furan.

20. The compound according to Claim 1 wherein m = 0 and **A** is $-CO_2H$.

21. The compound according to Claim 20 wherein R^1, R^2 and R^3 are hydrogen.

22. The compound according to Claim 2 wherein the group **–B-C** is attached to the phenyl ring at the 4-position.

23. The compound according to Claim 1 selected from the following table:















24. A compound represented by Formula II



II

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

n = 0 or 1;

R^3 is selected from the group consisting of: hydrogen and C_{1-4}alkyl, optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo and hydroxy;

each R^4 is independently selected from the group consisting of: halo, C_1-4alkyl and C_1-3alkoxy, said C_1-4alkyl and C_1-3alkoxy optionally substituted from one up to the maximum number of substitutable positions with halo.

25. The compound according to Claim 24 wherein n is 0.

26. The compound according to Claim 24 wherein n is 1.

27. The compound according to Claim 24 wherein R^3 is hydrogen.

28. The compound according to Claim 24 selected from the following table:





29. A compound represented by Formula III



III

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

n = 0 or 1;

R^3 is selected from the group consisting of: hydrogen and C_{1-4}alkyl, optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo and hydroxy;

each R^4 is independently selected from the group consisting of: halo, C_1-4alkyl and C_1-3alkoxy, said C_1-4alkyl and C_1-3alkoxy optionally substituted from one up to the maximum number of substitutable positions with halo.

30. The compound according to Claim 29 wherein n is 0.

31. The compound according to Claim 29 wherein n is 1.

32. The compound according to Claim 29 wherein R^3 is hydrogen.

33. The compound according to Claim 29 selected from the following table:



34. A method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient

a compound in accordance with Claim 1 in an amount that is effective for treating said immunoregulatory abnormality.

35. The method according to Claim 34 wherein the immunoregulatory abnormality is an autoimmune or chronic inflammatory disease selected from the group consisting of: systemic lupus erythematosis, chronic rheumatoid arthritis, type I diabetes mellitus, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, Graves ophthalmopathy and asthma.

36. The method according to Claim 34 wherein the immunoregulatory abnormality is bone marrow or organ transplant rejection or graft-versus-host disease.

37. The method according to Claim 34 wherein the immunoregulatory abnormality is selected from the group consisting of: transplantation of organs or tissue, graft-versus-host diseases brought about by transplantation, autoimmune syndromes including rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, posterior uveitis, allergic encephalomyelitis, glomerulonephritis, post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis, inflammatory and hyperproliferative skin diseases, psoriasis, atopic dermatitis, contact dermatitis, eczematous dermatitis, seborrhoeic dermatitis, lichen planus, pemphigus, bullous pemphigoid, epidermolysis bullosa, urticaria, angioedemas, vasculitis, erythema, cutaneous eosinophilia, lupus erythematosus, acne, alopecia areata, keratoconjunctivitis, vernal conjunctivitis, uveitis associated with Behcet's disease, keratitis, herpetic keratitis, conical cornea, dystrophia epithelialis corneae, corneal leukoma, ocular pemphigus, Mooren's ulcer, scleritis, Graves' opthalmopathy, Vogt-Koyanagi-Harada syndrome, sarcoidosis, pollen allergies, reversible obstructive airway disease, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, dust asthma, chronic or inveterate asthma, late asthma and airway hyper-responsiveness, bronchitis, gastric ulcers, vascular damage caused by

ischemic diseases and thrombosis, ischemic bowel diseases, inflammatory bowel diseases, necrotizing enterocolitis, intestinal lesions associated with thermal burns, coeliac diseases, proctitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease, ulcerative colitis, migraine, rhinitis, eczema, interstitial nephritis, Goodpasture's syndrome, hemolytic-uremic syndrome, diabetic nephropathy, multiple myositis, Guillain-Barre syndrome, Meniere's disease, polyneuritis, multiple neuritis, mononeuritis, radiculopathy, hyperthyroidism, Basedow's disease, pure red cell aplasia, aplastic anemia, hypoplastic anemia, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, agranulocytosis, pernicious anemia, megaloblastic anemia, anerythroplasia, osteoporosis, sarcoidosis, fibroid lung, idiopathic interstitial pneumonia, dermatomyositis, leukoderma vulgaris, ichthyosis vulgaris, photoallergic sensitivity, cutaneous T cell lymphoma, arteriosclerosis, atherosclerosis, aortitis syndrome, polyarteritis nodosa, myocardosis, scleroderma, Wegener's granuloma, Sjogren's syndrome, adiposis, eosinophilic fascitis, lesions of gingiva, periodontium, alveolar bone, substantia ossea dentis, glomerulonephritis, male pattern alopecia or alopecia senilis by preventing epilation or providing hair germination and/or promoting hair generation and hair growth, muscular dystrophy, pyoderma and Sezary's syndrome, Addison's disease, ischemia-reperfusion injury of organs which occurs upon preservation, transplantation or ischemic disease, endotoxin-shock, pseudomembranous colitis, colitis caused by drug or radiation, ischemic acute renal insufficiency, chronic renal insufficiency, toxinosis caused by lung-oxygen or drugs, lung cancer, pulmonary emphysema, cataracta, siderosis, retinitis pigmentosa, senile macular degeneration, vitreal scarring, corneal alkali burn, dermatitis erythema multiforme, linear IgA ballous dermatitis and cement dermatitis, gingivitis, periodontitis, sepsis, pancreatitis, diseases caused by environmental pollution, aging, carcinogenesis, metastasis of carcinoma and hypobaropathy, disease caused by histamine or leukotriene-C4 release, Behcet's disease, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, partial liver resection, acute liver necrosis, necrosis caused by toxin, viral hepatitis, shock, or anoxia, B-virus hepatitis, non-A/non-B hepatitis, cirrhosis, alcoholic cirrhosis, hepatic failure, fulminant hepatic failure, late-onset hepatic failure, "acute-on-chronic" liver failure, augmentation of chemotherapeutic effect, cytomegalovirus infection, HCMV infection, AIDS, cancer, senile dementia, trauma, and chronic bacterial infection.

38. The method according to Claim 34 wherein the immunoregulatory abnormality is multiple sclerosis.

39. The method according to Claim 34 wherein the immunoregulatory abnormality is rheumatoid arthritis.

40. The method according to Claim 34 wherein the immunoregulatory abnormality is systemic lupus erythematosus.

41. The method according to Claim 34 wherein the immunoregulatory abnormality is psoriasis.

42. The method according to Claim 34 wherein the immunoregulatory abnormality is rejection of transplanted organ or tissue.

43. The method according to Claim 34 wherein the immunoregulatory abnormality is inflammatory bowel disease.

44. The method according to Claim 33 wherein the immunoregulatory abnormality is a malignancy of lymphoid origin.

45. The method according to Claim 44 wherein the immunoregulatory abnormality is acute and chronic lymphocytic leukemias and lymphomas.

46. A method of suppressing the immune system in a mammalian patient in need of immunosuppression comprising administering to said patient an immunosuppressing effective amount of a compound of Claim 1.

47. A pharmaceutical composition comprised of a compound in accordance with Claim 1 in combination with a pharmaceutically acceptable carrier.